Systematic review: Infliximab therapy in ulcerative colitis

Alimentary Pharmacology and Therapeutics

Volumn 25, Issue 1, 2007, Pages 19-37

  Gisbert, J P ^a,b   Gonzalez Lama Y ^a   Mate J ^a  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^b NONE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; PLACEBO; STEROID; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CLINICAL TRIAL; COLON RESECTION; CONTROLLED CLINICAL TRIAL; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; HYPERTENSION; INFECTION; META ANALYSIS; NEPHROTOXICITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY CONTROL; REMISSION; SCORING SYSTEM; SEIZURE; SYSTEMATIC REVIEW; TREATMENT RESPONSE; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; CHILD; COLITIS, ULCERATIVE; DOUBLE-BLIND METHOD; GASTROINTESTINAL AGENTS; HUMANS; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 33845419436     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2006.03131.x     Document Type: Article

References (83)

1. Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J 1955; 4947: 1041-8.
2. Travis SP. Review article: the management of mild to severe acute ulcerative colitis. Aliment Pharmacol Ther 2004; 20 (Suppl. 4): 88-92.
3. Carbonnel F, Gargouri D, Lemann M, et al. Predictive factors of outcome of intensive intravenous treatment for attacks of ulcerative colitis. Aliment Pharmacol Ther 2000; 14: 273-9.
4. Faubion WA Jr, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001; 121: 255-60.
5. Shibolet O, Regushevskaya E, Brezis M, Soares-Weiser K. Cyclosporine A for induction of remission in severe ulcerative colitis. Cochrane Database Syst Rev 2005; 1: CD004277.
6. Durai D, Hawthorne AB. Review article: how and when to use ciclosporin in ulcerative colitis. Aliment Pharmacol Ther 2005; 22: 907-16.
7. Garcia S, Gisbert JP, Gomollon F. Cyclosporine in the treatment of severe attack of ulcerative colitis: a systematic review. Gastroenterol Hepatol 2005; 28: 607-14.
8. Rutgeerts P, Van Assche G, Vermeire S. Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology 2004; 126: 1593-610.
9. Siddiqui MA, Scott LJ. Infliximab: a review of its use in Crohn's disease and rheumatoid arthritis. Drugs 2005; 65: 2179-208.
10. Ardizzone S, Bianchi Porro G. Biologic therapy for inflammatory bowel disease. Drugs 2005; 65: 2253-86.
11. van Deventer SJ. Review article: targeting TNF alpha as a key cytokine in the inflammatory processes of Crohn's disease - the mechanisms of action of infliximab. Aliment Pharmacol Ther 1999; 13 (Suppl. 4): 3-8; discussion 38.
12. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999; 340: 1398-405.
13. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-9.
14. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004; 350: 876-85.
15. Rutgeerts P, Van Assche G, Vermeire S. Review article: infliximab therapy for inflammatory bowel disease - seven years on. Aliment Pharmacol Ther 2006; 23: 451-63.
16. D'Haens G. Infliximab for ulcerative colitis: finally some answers. Gastroenterology 2005; 128: 2161-4.
17. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12.
18. Seiderer J, Goke B, Ochsenkuhn T. Safety aspects of infliximab in inflammatory bowel disease patients. A retrospective cohort study in 100 patients of a German University Hospital. Digestion 2004; 70: 3-9.
19. Actis GC, Bruno M, Pinna-Pintor M, Rossini FP, Rizzetto M. Infliximab for treatment of steroid-refractory ulcerative colitis. Dig Liver Dis 2002; 34: 631-4.
20. Armuzzi A, De Pascalis B, Lupascu A, et al. Infliximab in the treatment of steroid-dependent ulcerative colitis. Eur Rev Med Pharmacol Sci 2004; 8: 231-3.
21. Armuzzi A, Lupascu A, De Pascalis B, et al. Infliximab in the treatment of glucocorticoid-dependent ulcerative colitis: a 54-week randomized methylprednisolone-controlled trial. Gastroenterology 2005; 128 (Suppl. 2): W1008.
22. Bermejo F, Lopez-Sanroman A, Hinojosa J, Castro L, Jurado C, Gomez-Beldal AB. Infliximab induces clinical, endoscopic and histological responses in refractory ulcerative colitis. Rev Esp Enferm Dig 2004; 96: 94-101.
23. Branciforte G, Terminella C, Bentivegna C, Scalia A, Catalano F. Is infliximab an useful therapeutic agent for ulcerative colitis? Gut 2002; 51 (Suppl. III): A217.
24. Castro Fernandez M, Garcia Diaz E, Romero M, Galan Jurado V, Rodriguez Alonso C. Treatment of steroid-refractory ulcerative colitis with infliximab. Gastroenterol Hepatol 2003; 26: 54-5.
25. Chey WY, Hussain A, Ryan C, Potter GD, Shah A. Infliximab for refractory ulcerative colitis. Am J Gastroenterol 2001; 96: 2373-81.
26. Chey WY. Infliximab for patients with refractory ulcerative colitis. Inflamm Bowel Dis 2001; 7 (Suppl. 1): S30-3.
27. Cooper JM, Patterson D, Thirlby RC. Infliximab for ulcerative colitis: not a cure for severe disease. Gastroenterology 2003; 124 (Suppl.1): 0A818.
28. De Falco R, Cirillo M, Gennarelli N, et al. Infliximab for the treatment of ulcerative recto-colitis unresponsive to conventional corticosteroid therapy. Endoscopic evaluation. Gut 2005; 54 (Suppl. VII): A155.
29. Eidelwein AP, Cuffari C, Abadom V, Oliva-Hemker M. Infliximab efficacy in pediatric ulcerative colitis. Inflamm Bowel Dis 2005; 11: 213-8.
30. Fleisher MR, Rubin SD, Levine AE, et al. Infliximab in the treatment of steroidnaïve ulcerative colitis. Am J Gastroenterol 2001; 96 (Suppl.): S291-2.
31. Frenz M, Simmons J, Travis S, Jewell D. Treatment and re-treatment of severe ulcerative colitis with infliximab: a case study. Inflamm Bowel Dis Monitor 2002; 3: 119-20.
32. Gornet JM, Couve S, Hassani Z, et al. Infliximab for refractory ulcerative colitis or indeterminate colitis: an openlabel multicentre study. Aliment Pharmacol Ther 2003; 18: 175-81.
33. Jarnerot G, Blombert B, Bohr J, Curman B, Sandberg-Gertzén H. Infliximab (Remicade) as rescue therapy in acute corticosteroid-resistant ulcerative colitis (UC). Scand J Gastroenterol 2001; 36 (Suppl. 233): 08.
34. Jarnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005; 128: 1805-11.
35. Jølle T, Guanglin C, Goll R, et al. Anti-TNF-alpha (infliximab) treatment suppresses tissue TNF-alpha mRNA expression and induces clinical remission in ulcerative colitis. Gut 2004; 53 (Suppl. VI): A310.
36. Kaser A, Mairinger T, Vogel W, Tilg H. Infliximab in severe steroid-refractory ulcerative colitis: a pilot study. Wien Klin Wochenschr 2001; 113: 930-3.
37. Kohn A, Prantera C, Pera A, Cosintino R, Sostegni R, Daperno M. Anti-tumour necrosis factor alpha (infliximab) in the treatment of severe ulcerative colitis: result of an open study on 13 patients. Dig Liver Dis 2002; 34: 626-30.
38. Kohn A, Prantera C, Pera A, Cosintino R, Sostegni R, Daperno M. Infliximab in the treatment of severe ulcerative colitis: a follow-up study. Eur Rev Med Pharmacol Sci 2004; 8: 235-7.
39. Kountouras J, Zavos C, Chatzopoulos D. Anti-tumor necrosis factor therapy for ulcerative colitis. Gastroenterology 2005; 129: 1138-9.
40. Sapakos I, Gavalas E, Zavos C, et al. Infliximab administration in patients with ulcerative colitis. In: Proceedings of the Fourth Panhellenic Congress of Inflammatory Bowel Diseases. Thessaloniki, Greece, 2005: 234.
41. Kugathasan S, Prajapati D, Kim CP, et al. Infliximab outcome in children and adults with ulcerative colitis. Gastroenterology 2002; 120: A615.
42. Lim W, Sparrow MP, Hanauer S. The efficcacy of infliximab (INF) in ulcerative colitis (UC) - the University of Chicago's experience. Gastroenterology 2005; 128 (Suppl. 2): W1035.
43. Ljung T, Karlen P, Schmidt D, et al. Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County. Gut 2004; 53: 849-53.
44. Mamula P, Markowitz JE, Brown KA, Hurd LB, Piccoli DA, Baldassano RN. Infliximab as a novel therapy for pediatric ulcerative colitis. J Pediatr Gastroenterol Nutr 2002; 34: 307-11.
45. Mamula P, Markowitz JE, Cohen LJ, von Allmen D, Baldassano RN. Infliximab in pediatric ulcerative colitis: two-year follow-up. J Pediatr Gastroenterol Nutr 2004; 38: 298-301.
46. McGinnis JK, Murray KF. Infliximab for ulcerative colitis in children. J Pediatr Gastroenterol Nutr 2004; 39 (Suppl. 1): S282.
47. Ochsenkuhn T, Sackmann M, Goke B. Infliximab for acute, not steroid-refractory ulcerative colitis: a randomized pilot study. Eur J Gastroenterol Hepatol 2004; 16: 1167-71.
48. Oliva-Hemker M, Roper S, Cuffari C, Leibowitz I. Infliximab therapy for pediatric ulcerative colitis. Gastroenterology 2002; 122: A616.
49. Probert CS, Hearing SD, Schreiber S, et al. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut 2003; 52: 998-1002.
50. Ruiz P, San Salvador P, Ortiz de Zarate J, et al. Infliximab as treatment for a severe outbreak of ulcerative colitis. Gastroenterol Hepatol 2004; 27: 430-1.
51. Russell GH, Katz AJ. Infliximab is effective in acute but not chronic childhood ulcerative colitis. J Pediatr Gastroenterol Nutr 2004; 39: 166-70.
52. Rutgeerts P, Feagan B, Olson A, et al. A randomized placebo-controlled trial of infliximab therapy for active ulcerative colitis: Act I trial. Gastroenterology 2005; 128 (Suppl. 2): 689.
53. Sandborn WJ, Feagan B, Olson A, et al. A randomized placebo-controlled trial of infliximab therapy for active ulcerative colitis: Act I trial results through week 54. Am J Gastroenterol 2005; 100 (Suppl): S313.
54. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462-76.
55. Sandborn WJ, Rachmilewitz D, Hanauer S, et al. Infliximab induction and maintenance therpay for ulcerative colitis: the Act 2 trial. Gastroenterology 2005; 128 (Suppl.2): 688.
56. Sands BE, Tremaine WJ, Sandborn WJ, et al. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis 2001; 7: 83-8.
57. Serrano MS, Schmidt-Sommerfeld E, Kilbaugh TJ, Brown RF, Udall JN Jr, Mannick EE. Use of infliximab in pediatric patients with inflammatory bowel disease. Ann Pharmacother 2001; 35: 823-8.
58. Sriram PV, Reddy KS, Rao GV, Santosh D, Reddy DN. Infliximab in the treatment of ulcerative colitis with toxic megacolon. Indian J Gastroenterol 2004; 23: 22-3.
59. Su C, Salzberg BA, Lewis JD, et al. Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis. Am J Gastroenterol 2002; 97: 2577-84.
60. Shen EH, Das KM. Current therapeutic recommendations: infliximab for ulcerative colitis. J Clin Gastroenterol 2004; 38: 741-5.
61. Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002; 347: 417-29.
62. Murch SH, Lamkin VA, Savage MO, Walker-Smith JA, MacDonald TT. Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease. Gut 1991; 32: 913-7.
63. Lichtenstein GR. Is infliximab effective for induction of remission in patients with ulcerative colitis? Inflamm Bowel Dis 2001; 7: 89-93.
64. Nielsen OH, Gionchetti P, Ainsworth M, et al. Rectal dialysate and fecal concentrations of neutrophil gelatinase-associated lipocalin, interleukin-8, and tumor necrosis factor-alpha in ulcerative colitis. Am J Gastroenterol 1999; 94: 2923-8.
65. Ishiguro Y. Mucosal proinflammatory cytokine production correlates with endoscopic activity of ulcerative colitis. J Gastroenterol 1999; 34: 66-74.
66. Guimbaud R, Bertrand V, Chauvelot-Moachon L, et al. Network of inflammatory cytokines and correlation with disease activity in ulcerative colitis. Am J Gastroenterol 1998; 93: 2397-404.
67. Saiki T, Mitsuyama K, Toyonaga A, Ishida H, Tanikawa K. Detection of pro- and anti-inflammatory cytokines in stools of patients with inflammatory bowel disease. Scand J Gastroenterol 1998; 33: 616-22.
68. Reimund JM, Wittersheim C, Dumont S, et al. Mucosal inflammatory cytokine production by intestinal biopsies in patients with ulcerative colitis and Crohn's disease. J Clin Immunol 1996; 16: 144-50.
69. Reinecker HC, Steffen M, Witthoeft T, et al. Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol 1993; 94: 174-81.
70. Tsukada Y, Nakamura T, Iimura M, Iizuka BE, Hayashi N. Cytokine profile in colonic mucosa of ulcerative colitis correlates with disease activity and response to granulocytapheresis. Am J Gastroenterol 2002; 97: 2820-8.
71. Watkins PE, Warren BF, Stephens S, Ward P, Foulkes R. Treatment of ulcerative colitis in the cottontop tamarin using antibody to tumour necrosis factor alpha. Gut 1997; 40: 628-33.
72. Evans RC, Clarke L, Heath P, Stephens S, Morris AI, Rhodes JM. Treatment of ulcerative colitis with an engineered human anti-TNFalpha antibody CDP571. Aliment Pharmacol Ther 1997; 11: 1031-5.
73. A-Rahim YI, Farrell RJ. Anti-tumor necrosis factor therapy in ulcerative colitis. UpToDate 2005; 13: 1-6.
74. Jarnerot G, Rolny P, Sandberg-Gertzen H. Intensive intravenous treatment of ulcerative colitis. Gastroenterology 1985; 89: 1005-13.
75. Rossetti S, Actis GC, Fadda M, Rizzetto M, Palmo A. The use of the anti-tumour necrosis factor monoclonal antibody - infliximab - to treat ulcerative colitis: implications and trends beyond the available data. Dig Liver Dis 2004; 36: 426-31.
76. Fuss IJ. Treatment of ulcerative colitis with infliximab: are we there yet? J Pediatr Gastroenterol Nutr 2004; 38: 247-9.
77. MacDermott RP, Lichtenstein GR. Infliximab (Remicade) in Crohn's disease. UpToDate 2005; 13: 1-11.
78. Parsi MA, Achkar JP, Richardson S, et al. Predictors of response to infliximab in patients with Crohn's disease. Gastroenterology 2002; 123: 707-13.
79. Blomberg B, Jarnerot G. Clinical evaluation and management of acute severe colitis. Inflamm Bowel Dis 2000; 6: 214-27.
80. Arts J, D'Haens G, Zeegers M, et al. Long-term outcome of treatment with intravenous cyclosporin in patients with severe ulcerative colitis. Inflamm Bowel Dis 2004; 10: 73-8.
81. Lichtenstein GR, Abreu MT, Cohen R, Tremaine W. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 2006; 130: 940-87.
82. Su C. Outcomes of placebo therapy in inflammatory bowel disease. Inflamm Bowel Dis 2006; 12: 328-33.
83. Jarnerot G. Infliximab or cyclosporine for severe ulcerative colitis. Gastroenterology 2006; 130: 286, author reply 287.